ValGenesis Innovations Days Event Brief
ValConnect Innovation Days convened more than 30 life sciences organizations across Lisbon, Portugal, and Research Triangle Park, North Carolina, to examine how artificial intelligence, digital validation, and end to end life cycle execution are changing regulated operations.
David Medina, chief marketing officer at ValGenesis, framed the purpose of the series: “ValConnect Innovation Day brings together life sciences leaders to share practical experiences and explore how AI and digital transformation are shaping the future of end-to-end life cycle execution.”
Image Source: ValGenesis
The signal was clear. Life Sciences is moving from paper-based execution and document centric evidence toward digital, data driven, and intelligence enabled operating models.
Building Community to Drive Collaboration
The programs were built around peer learning, customer experience, expert discussion, and practical demonstration. Life sciences companies are no longer debating whether digital validation and AI belong in regulated operations. They are evaluating how these capabilities should be applied, governed, scaled, and trusted.
Medina also emphasized the event’s peer learning model. “ValConnect Innovation Day is designed to create a space where life sciences professionals can learn directly from their peers.”
That peer orientation is important. Regulated transformation advances when organizations share implementation experience, not just technology ambition.
“By bringing the community together in these collaborative spaces, we ensure that our AI innovations like those powering the iClean™ platform are grounded in the real-world complexities our customers face every day.” – Dave Medina, Chief Marketing Officer, ValGenesis
Image Source: ValGenesis
This is the right test for AI in life sciences. It must work in real processes, with real constraints, under real regulatory expectations.
These events also introduced a practical framework for evaluating AI autonomy by examining where AI should advise, assist, and act. Regulated organizations should not treat autonomy as a binary decision. They need graduated models that connect intended use, risk, process criticality, evidence requirements, and human oversight.
Across both events, three themes emerged.
These themes align with Axendia’s broader research narrative. The 2026 Life Sciences Radar frames continuous disruption as a defining industry condition. Axendia’s AI market research shows growing momentum behind AI adoption, while also highlighting the difference between innovators scaling beyond pilots, followers evaluating use cases, and laggards with limited near-term adoption plans. The common thread is maturity. Scalable impact requires data readiness, governance, integration, workforce readiness, and operational discipline.
Lisbon Insights
The Lisbon event focused on digital transformation, end to end life cycle execution, and product development. Customer presentations from Pharmascience and UCB showed how organizations are scaling digital validation and development initiatives while applying Quality by Design and Quality Risk Management.
The implication is significant. Quality by Design and Quality Risk Management are established industry practices. Connected digital platforms create the opportunity to apply them with greater consistency across the lifecycle. The broader value is lifecycle continuity. When product development, validation, and quality data are connected, organizations can reduce handoffs, improve traceability, and strengthen process knowledge.
RTP Insights
The RTP event, hosted at Sequence Inc.’s headquarters, extended the discussion into practical AI applications across the product life cycle. Sessions addressed cleaning validation, commissioning and qualification, and knowledge management.
The ValGenesis iClean demonstration within Sequence’s mock pharmaceutical manufacturing facility provided a practical example. Cleaning validation can be managed digitally from planning and execution through data collection, review, and lifecycle management. The value is not only efficiency. It is better control of a complex, data intensive process tied directly to contamination control and product quality.
Axendia Participation
Image Source: ValGenesis
I was honored to deliver keynote addresses in both Lisbon and RTP. The keynote, “From Digital to Intelligent: The Next Era in Life Sciences,” examined how leading companies are moving from systems of record to systems of intelligence as AI becomes an enterprise capability.
The session discussed how Intelligence, not documentation alone, will define the next phase of operational excellence. Digital transformation created the foundation. The next advantage will come from governed systems that accelerate decisions, reduce risk, and help organizations move faster with confidence.
The keynote also connected Axendia’s latest AI market research with the operational realities discussed throughout the events, including time to market, time to volume, quality, compliance, patient outcomes, and resilience.
In addition, we reinforced that message during panel discussions at both Lisbon and RTP. The executive panel, “Powering Life Sciences with Digital Innovation,” examined real world applications, key challenges, and how organizations can leverage digital innovation to accelerate development, improve compliance, and drive future growth.
Image Source: VaGenesis
Fabrizio Maniglio, vice president of digital transformation at ValGenesis, moderated both panels.
Lisbon Panelists:
RTP Panelists:
In Brief
ValConnect Innovation Days showed an industry moving from AI curiosity to AI discipline. Leaders are asking where AI should advise, assist, and act. Speed, compliance, and confidence must advance together.
Image Source: ValGenesis
End to end life cycle execution is becoming part of the enterprise intelligence layer. It is no longer enough to complete required documents and retain evidence. Organizations must capture, structure, contextualize, and govern validation data so they can understand process state, evaluate risk, connect decisions to evidence, and maintain control across the lifecycle.
Leaders must prioritize trusted data foundations, strong governance, operational alignment, workforce capability, human oversight, and scalability. They should avoid isolated pilots that do not connect to validated processes, quality systems, or enterprise data strategies.
We will continue to provide updates on Valgenesis as they become available.
To discuss how this initiative impacts your organization, click on this link to schedule an Analyst Inquiry on this topic.
The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.